|
Accueil > Actualité
Amgen: EPS up 13% in Q4
(CercleFinance.com) - Amgen has reported Q4 2024 adjusted EPS that is up 13% to $5.
31, with non-GAAP operating margin down 0.4 point to 46.3%, while revenues rose 11% to $9.1bn. Product sales were up 11%, with volume growth of 14%, with ten products recording revenue growth of at least 10%, including Repatha, Blincyto, Tezspire, Evenity and Tavneos. Posting adjusted EPS of $19.84 and revenues of $33.4bn for FY 2024, the healthcare group expects respective target ranges between $20 and $21.20 and between $34.3bn and $35.7bn in 2025. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
06/05/2025 07:07
Rubiscroissance de 2% du CA trimestriel 05/05/2025 18:33 Crédit Agricolenouveau président du conseil de CA CIB 05/05/2025 18:27 Vincisigne une convention de rachat d'actions 05/05/2025 18:21 Elisconfirme l'ensemble de ses objectifs financiers 05/05/2025 18:12 GTTva acquérir 100% de la société Danelec 05/05/2025 18:06 Cofacerésultat net pdg de 62,1 ME au 1er trimestre Tous les articles sociétés |
